They may have provided additional insight for the interaction between GV and sodium-glucose cotransporter 2 inhibitors on clinical outcomes because sodium-glucose cotransporter 2 inhibitor is a novel treatment option for improving clinical outcomes in patients with HF with reduced and preserved ejection fraction [38, 39]. Here, SLC5A2 is linked to hydrops fetalis.